Product Name: KinSub1DDLYY
Product Number: PE-01AGT95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub1DDLYY

Product Use: For assaying the phosphotransferase activity of B lymphoid tyrosine kinase (Blk, UniProt ID P51451). The KinSub1DDLYY peptide demonstrated very high phosphotransferase activity with Blk, and exhibited moderate specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub1DDLYY was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: HGGEDDLYYAPGGGG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1463.5 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Blk

Scientific Background: Blk is one of several protein kinases that can phosphorylate KinSub1DDLYY. Human Blk (also known as B lymphoid kinase) is a protein-tyrosine kinase of 505 amino acid length, with a predicted molecular mass of 57,706 Da. It is a member of the TK group of protein kinases in the Src family. It has been reported that Blk is expressed specifically in the B cell lineage and plays a role in signal transduction pathway that is restricted to B lymphoid cells (1). However, this kinase has low to reasonably high expression (e.g. skeletal muscle, kidney, thyroid, breast) in most tested human tissues except in the brain and spinal cord where it is poorly expressed. Orthologues of Blk are highly conserved in mammals and birds. Blk is inhibited by phosphorylation at Y501. Blk has been linked with the development of colorectal adenocarcinomas. Stimulation of resting B-lymphocytes with antibodies to surface immunoglobulin (sIgD or sIgM) induces activation of Blk (2).